Fig. 4From: Clinical outcomes of immune checkpoint inhibitors to treat non-small cell lung cancer patients harboring epidermal growth factor receptor mutationsA Comparison of progression-free survival (PFS) between the groups categorized according to prior EGFR-TKI resistance. B Comparison of overall survival (OS) between the groups categorized according to prior EGFR-TKI resistanceBack to article page